Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIS1 in Relapsed/Refractory Peripheral T Cells Lymphoma (PTCL)
NCT06495723Phase 2Recruiting
- Sponsor
- Xenothera
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of LIS1 in peripheral T-cell lymphoma (PTCL) (4 arms), sponsored by Xenothera. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment Emergent Adverse Events and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
LIS1
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06495723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495723.